Abstract | The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics, despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free survival and overall survival, although the cure rates have been affected only modestly. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, growth in our armamentarium offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial 'ovarian' cancer and describes the direction and early results of clinical investigation.
Introduction
Characterized by late-stage presentation, metastatic bulky disease burden ( Figure 1 ) and stagnant mortality statistics despite prolific drug development, ovarian cancer is facing a renaissance of discovery. These advances are fuelling renewed expectations that this disease might be more efficiently combated to impact outcomes. 1 Convincing evidence already exists to indicate that the term 'ovarian' cancer (including primary peritoneal carcinoma) might be a misnomer, with a signifi cant proportion of primary 'ovarian' tumours arising from malignant transformation of secretory cells in the fallopian tube. 2 In addition, genomic characterization of different histologies, such as low-grade serous, mucinous, clear cell and endometrioid tumours, has revealed heterogeneity in leveraged pathways for prolifer ation and invasion. 3, 4 Even interrogation of the most common histo logy, high-grade serous, has revealed that it could be subclassified by genomic signatures that suggest a variety of different pathways and response elements guiding their intrinsic biology. [5] [6] [7] [8] [9] This emerging knowledge base is starting to guide and inform clinical investigation, most obviously therapeutics. Additionally, the tumour microenvironment has emerged as an important target with antiangiogenesis therapies and immunological approaches leading the way. 10 However, it is also likely that informatics will guide the paradigm of treatment, including surgical intervention and strategic sequencing of therapy in the near future. 11 In light of the developing database of therapeuti c in formation and emerging technology directing clinica l trial development, we provide a review of the clinical state of the disease. Herein, we address the latest results from clinical trials at the key management decision points throughout the natural history of the disease. Global contribution from investigators and cooperative groups has provided a plethora of treatment options, which is expected to expand, but likely in a more-selective and individualized fashion. Although under-pacing discovery, growth in our armamentarium should enable more individualized treatment options in an attempt to increase the pace of improved survivorship.
Surgery
The role of surgery The role of surgery in the treatment of ovarian cancer is pivotal to achieve the goal of maximally extendin g survival. There are essentially three goals of surgical intervention for patients with suspected ovarian malignancies: establishing the diagnosis, staging, and c ytoreduction or debulking.
Establishing the diagnosis
Establishing the diagnosis might sound elementary; however, in the face of widespread disease, a myriad of solid tumours, including gastrointestinal, can mimic ovarian cancer at initial presentation. Often, immunohistochemical and other protein-expression biomarker tests, in combination with sophisticated imaging and endoscopy procedures, are necessary to accurately identify the site of malignant origin when widespread intraperitoneal disease exists. Furthermore, the histological confirmation of a cancer diagnosis is often made initially at surgery, as needle biopsy of large ovarian masses is generally discouraged for fear of disease spread or upstaging patients.
Staging
Determining the extent, or stage (Box 1), of disease is of particular importance for those patients who have what seems to be cancer confined to the ovary. Accurate staging can guide treatment and offers valuable prognostic information. Multiple reports have demonstrated that occult disease is identified nearly a third of the time when comprehensive surgical staging is conducted. [12] [13] [14] [15] Cytoreduction or debulking The current standard of care for patients with di sseminated disease is maximal surgical cyto reduction.
Although such an approach is rarely practiced in other non-gynaecological tumours, cytoreduction in patients with ovarian cancer patients provides opportu nities to accurately establish a diagnosis, to remove poorly perfused or under oxygenated tissue that may harbour chemo resistant disease, and to favourably alter the tumour microenvironment to enhance adjuvant therapy. 14, 16 Although no prospective randomized trial has been conducted to examine the impact of residual disease on overall survival, removal of greater amounts of tumour has consistently been associated with better outcomes. The first report on the topic dichotomized postoperative tumour residuum to less than or greater than 1.5 cm. 17 Patients left with disease greater than 1.5 cm had a median overall survival of 12 months; those found with either 1.5 cm of disease or less or in whom debulking rendered them with the same disease volume had an overall survival of 26 months. Since then, the definition has varied between less than 2 cm of residual disease to no gross residual disease. 18 In more-contemporary accounts, optimal cytoreduction is defined as removing all disease 1 cm or greater in diameter, leaving visible, but small-volume disease at the completion of surgery. 12, 14 However, recently many clinicians have proposed that the true goal of radical cytoreduction should be to reduce tumour to no grossly visible tumour. 19 This suggestion stems from several systematic review articles that demonstrated a significant survival variance in tumour residuum below 1 cm. 14, 19, 20 Although radical resection procedures, such as intestinal resection, diaphragm stripping or resection, splenectomy and liver resection might be necessary to achieve this result, complete resection seems to be feasible in approximately a quarter of patients. 19, 20 It is still controversial whether disease that is amenable to complete resection is functionally driven by a different biology than instances for which resection is not feasible.
Timing of surgery-primary versus interval
Despite the relationship between cytoreduction o ut come and overall survival, investigators have not been able to identify an externally validated method to choose which patients are best suited for primary surgical cyto reduction, although several nomograms have been described. 21 An alternative strategy leverages the innate chemosensitivity that frequently characterizes ovarian cancer at presentation, that is, neoadjuvant chemo therapy. The concept of neoadjuvant chemotherapy, whereby chemotherapy is administered prior to compre hensive surgical cytoreduction, has been a topic of signifi cant interest in the treatment of frontline ovarian cancer for the past decade. Patients who are thought to benefit include those with significant medical comorbidi ties and those with a priori non-debulkable tumours. Proponents of neoadjuvant chemotherapy have cited the improved or at least non-inferior diseasefree survi val and overall survival associated with the approach and the improved ability of the surgeon to achieve a state of optimal cytoreduction otherwise known as complete resection. 13, 16, [22] [23] [24] [25] Most of the studies
Key points
■ Ovarian cancer continues to be characterized by late-stage presentation and bulky intraperitoneal disease burden at presentation ■ Surgery and chemotherapy are the mainstays of primary therapy;
'optimal' surgical cytoreduction is being re-defined as resection of all macroscopic disease ■ Advances in adjuvant chemotherapy have leveraged intraperitoneal administration, dose-dense paclitaxel and the addition of biological agents predominately targeting angiogenesis ■ Maintenance therapy is a promising strategy as a primary or subsequent adjuvant approach, but as yet is not been proven to increase overall survival ■ Recurrence therapy has improved post-progression outcomes, although cures are elusive ■ Closely tied to a wider understanding of the underlying biology of ovarian cancer, drug development is increasingly focused on specific new targets in the hope of optimizing the therapeutic index that have compared primary surgical cytoreduction with neoadjuvant chemotherapy followed by interval cyto reduction have demonstrated overall decreased surgical morbidity and mortality for the neoadjuvanttherapy group. The tolerability advantages that favour neoadjuvant therapy have included: decreased estimated blood loss, shorter surgical times, less intensive-care-unit admissions, fewer bowel resections, and reduced overall lengths of stay. 13, 16, [22] [23] [24] [25] [26] Overall operative morbidity is clearly reduced when neoadjuvant therapy is employed.
Some authors, however, have challenged that neoadjuvant chemotherapy may, in fact, be associated with poorer than expected overall survival. [27] [28] [29] The controversy was not resolved with the publication of the only phase III randomized trial to prospectively compare the outcomes of primary debulking with neoadjuvant chemo therapy and interval cytoreduction in women with stage III-IV bulky primary ovarian cancer. 30 Despite demonstrating that the neoadjuvant approach was not inferior to primary surgical cytoreduction and was associ ated with less morbidity, the absolute values of resection to <1 cm (41% overall) and progression-free survival (PFS) and overall survival in the neodjuvanttherapy group were substantially lower than expected (12 months and 30 months, respectively). Indeed, Chi et al., 31 have countered that patients enrolled at their institution-meeting the same eligibility criteria as the Vergote et al. 30 study-over the same enrollment period, fared much better with primary surgery and that the outcomes in the randomized trial seemed to be more consistent with their large-volume residual disease (suboptimal) patient population. Recently, Vergote et al. 26 have suggested that in patients with large-volume disease, neoadjuvant therapy might be preferred, yet the overall survival is not impressive even in the experi mental neoadjuvant cohort (Table 1) . A recent meta-analysis conclu ded that interval debulking surgery should not be the preferred approach to primary debulking surgery, 32 yet as stated, the only phase III data currently available demonstrates similar efficacy and improved toxicity with the neoadjuvant approach. Thus, the debate continues (Box 2), and the hope is that ongoing trials of interval versus primary cytoreduction [33] [34] [35] will better define the best option for patients while addressing perceived short-comings of the present trial.
Second-look surgery A second-look procedure is defined as a reassessment procedure that is conducted in patients who have had a complete clinical response to primary treatment following surgery and adjuvant therapy. Thus, physical exam, as well as assessment of tumour markers and imaging, is normal. The procedure is not to be confused with interval cytoreduction or secondary cyto reduction. Second-look procedures, despite a long history of use, have fallen out of favour as a standard intervention largely owing to a lack of clinical benefit or influence on overall survival. 36 Improper use might result in direct harm to patients with unnecessary expense, pain, and inconveni ence. However, second-look operations can be a valuable asset when used within the context of a clinical trial to confirm a pathological complete response (pCR) or to identify small-volume residual disease amenable to experimental therapy. The expanding role of minimally invasive surgery might increase the therapeutic index in these cases.
Chemotherapy and novel agents
First-line therapy With the publication of the results of the Gynecologic Oncology Group (GOG) protocol 111 in 1996, intra venous paclitaxel replaced intravenous cyclophosphamide in the adjuvant treatment of advancedstage ovarian cancer. 37 This study randomly assigned 410 women with advanced-stage ovarian cancer and residual disease larger than 1 cm after initial surgery to receive cisplatin (75 mg/m 2 ) with either cyclophosphamide (750 mg/m 2 ) or paclitaxel (135 mg/m 2 over 24 h). Among the 216 women with measurable disease, 73% on the cisplatin-paclitaxel arm responded to treatment, compared with 60% receiving the cisplatincyclophosphamide regimen (P = 0.01). PFS was significantly longer (P <0.001) in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group (median PFS 18 months and 13 months, respectively). Median overall survival was also significantly longer (P <0.001) in the cisplatin-paclitaxel group (38 months versus 24 months). The paradigm of switching from cyclo phosphamide to paclitaxel was later confirmed in a European and Canadian phase III clinical trial (EORTC-NCIC OV 10). 38 This 680-patient study enrolled a broader patient population than GOG 111 and administered paclitaxel as a 3-h infusion instead of over 24 h. After a median follow-up of 38.5 months and despite a high rate of crossover (48%) from the cyclo phosphamide arm to the paclitaxel arm at first relapse, a longer median PFS (P = 0.0005; 15.5 months versus 11.5 months) and overall survival (P = 0.0016; 35.6 months versus 25.8 months) was seen.
Two, more recent, randomized phase III trials led to the replacement of cisplatin with carboplatin when combined with paclitaxel. This regimen is widely accepted around the world as one of the current standards in treating ovarian cancer both in advanced-stage cases after debulking surgery as well as those cases with early stage disease following surgical staging. Both studies were non-inferiority phase III trials comparing paclitaxel plus cisplatin with paclitaxel plus carboplatin in patients with advanced-stage ovarian cancer; the latter regimen being better tolerated and easier to deliver in an outpatient setting. Since the two studies investigated different doses, the optimal doses remain unclear. The German study 39 used a carboplatin dose calculated using the method of Calvert, 40 in which the required dose is obtained by the formula: carboplatin (dose in milligrams = AUC = 6 × [glomerular filtration rate + 25]) plus paclitaxel (185 mg/m 2 over 3 h). The glomerular filtration rate was estimated using the Jelliffe formula. 41 The GOG study used a dose of intravenous carboplatin (AUC = 7.5) plus paclitaxel (175 mg/m 2 over 3 h). Either dose is acceptable. Patients with small-volume residual disease (<1 cm) treated with intravenous carboplatin plus paclitaxel in the GOG study had a median overall surviv al of 57.4 months compared with 48.7 months for the cisplatin and paclitaxel arm. 42 Most recently, the dose and schedule of paclitaxel has been questioned. A single study in Japan has suggested that intravenous paclitaxel given weekly at 80 mg/m 2 combined with standard doses and schedules of carboplatin can allow dose intensification resulting in prolonged PFS and overall survival. 43 The analysis included 631 patients; at 6.4 years of median follow-up, the median PFS after administration of weekly paclitaxel was 28.1 months compared to 17.5 months in the control arm (schedule every 3 weeks, HR = 0.75; 95% CI 0.62-0.91; P = 0.0037). Median survival has not yet been reached, but the overall survival at 5 years was also higher in the dose-dense weekly group (58.6% versus 51.0%; HR = 0.79; 95% CI 0.63-0.99; P = 0.0448). 43 Such a strategy has been validated when treating patients with metastatic breast cancer. 44 This idea is being tested by the GOG and the results are eagerly awaited. 45 The administration of intraperitoneal chemo therapy has also generated much controversy. By giving chemotherapy via the peritoneum, a pharmacological advantage is created, but randomized trials have shown this approach to be toxic and direct comparisons of equivalent doses and schedules of agents administered intra venously or intraperitoneally have been scarce. 46 The study that has generated the most disagreement is GOG 172. 47 This study showed that intraperitoneal therapy increased overall survival from 49.7 months to 65.6 months compared to intravenous therapy (P = 0.03) in patients with small-volume residual disease (<1 cm) following surgery. Importantly, the intraperitoneal arm of GOG 172 also incorporated a higher dose of cisplatin and weekly treatments into the intraperitoneal arm; thus, making direct comparison of the results impossible. 48 A well-designed study of intraperitoneal therapy has c ompleted enrolment and should report soon. 49 The most recent advance in treating newly diagnosed ovarian cancer is adding bevacizumab, an anti-VEGF monoclonal antibody, to front-line intravenous carboplatin and paclitaxel at the doses and schedules discussed above. Angiogenesis has a fundamental role in normal ovarian physiology as well as in the patho genesis of ovarian cancer, promoting tumour growth and progression through ascites formation and metastatic spread. 50 Two phase III trials have shown that adding bevacizumab to the chemotherapy backbone prolongs PFS (Table 2) . 51, 52 Each of the aforementioned strategies has had an impact on the primary treatment standard for ovarian cancer. However, globally there are significant practice variations owing to patient cohorts (Asian versus other), residual disease (optimal versus all comers) and drug regulatory approval (bevacizumab).
Maintenance therapy
Although advances in primary surgery and adjuvant therapy have induced high rates of complete remission following therapy, maintaining disease-free status has been elusive. Indeed, many patients develop recurrent disease, even after a negative second-look operation or pCR; for example, there was a high rate of recurrence (45%) in patients with a negative second-look laparotomy. 53 Patients who initially had high-stage and high-grade tumours were more likely to have disease Red blood cell transfusion 53% 51%
Abbreviations: IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery; PFS, progression-free survival.
Box 2 | Pros and cons of neoadjuvant chemotherapy
Pros ■ Less peri-operative morbidity and mortality ■ Start chemotherapy faster ■ Rapidly identify refractory patients ■ Outcomes generally seem to be comparable with primary cytoreduction in terms of survival ■ Phase III outcomes data are available and supportive ■ Less aggressive and specialized surgical procedures may be necessary Cons ■ Increases theoretical odds of resistance ■ Chemotherapy might be less effective ■ Lost opportunity to cytoreduce ■ Less amenable to intraperitoneal therapy ■ Survival data worse than contemporary primary debulking surgery data ■ Major criticisms of surgical skill or effort and patient selection in trials recurrence after a negative second-look operation. 54 However, those who were disease free at 5 years were likely to remain disease free at subsequent follow-up. Nonetheless, this high recurrence risk has prompted several investigators to consider additional treatment once a complete response to primary treatment is identi fied. 55 This treatment is often termed maintenance or consolidation therapy, although the former term is favoured, given that the decision for treatment is based on the effect of primary therapy. Several randomized and nonrandomized clinical trials have been conducted in this arena, including treatment with hormones, vitamins, radiation therapy, standard and high-dose chemo therapy, radioimmunoconjugates, immunotherapy, vaccines, gene therapy, biological therapy, complementary medicines, and holistic approaches. 56 These trials have been difficult to interpret because they have included patients with either partial or complete response to front-line therapy, inclusion of second-line therapy patients, inclusion of treatment in both arms of the study or are limited by sample size or clinical trial bias. A recent Cochrane Review of the subject concluded that no treatment effect on PFS or overall survival could be demonstrated among the limited sample of phase III trials, which randomized patients with complete clinical response (cCR) to treatment versus placebo or observation. 57 Importantly, this Review did not include the two bevacizumab trials discussed above, 51, 52 as these trials allowed patients with clinical partial response to proceed onto the randomized maintenance strategy. Subsequent to the Cochrane Review, another phase III trial of erlotinib (versus observation) was reported. This GCIG/ EORTC-GCG trial randomly assigned 835 patients with high-risk stage I-IV disease who achieved a cCR when receiving platinum-based chemotherapy. Erlotinib (150 mg/day) was administered for 2 years; the primary end point was PFS. Unfortunately, neither PFS (median 12.7 months versus 12.4 months) nor overall survival (median 51 months versus 59 months) were impacted by therapy. No subgroup seemed to benefit, including the small sample of patients with EGFR mutation. 58 An ongoing phase III trial, GOG-212, 59 which is comparing the effect of two taxanes (paclitaxel and paclitaxel polyglutamate) to no further treatment in patients achieving cCR after front-line therapy is poised to address the impact that taxane-based maintenance treatment might have on overall survival. The trial was launched in response to a phase III trial, GOG 178, which randomly assigned patients with advanced-stage ovarian cancer who were in cCR to either 3 or 12 additional months of paclitaxel. 60 The trial was designed to accrue 450 patients; however, at a planned interim analysis (after 277 patients were randomized), a statistically significant benefit for the longer treatment was demonstrated and the study was closed to further accrual. The report demonstrated a 7-month improvement in median PFS (21 months versus 14 months; P = 0.006) and was not powered to show an effect on overall survival.
Several additional biological agents are being evaluated in the phase III setting in designs that mimic ICON7 and GOG218. These include nintedanib (a small-molecule inhibitor of VEGFR, FGFR and PDGFR) 61 and trebananib (an angiopoietin 1 and 2 neutralizing peptibody), 62 both including concomitant therapy versus placebo followed by single agent (or placebo) continuation for those patients achieving at least a partial response. In addition, pazopanib is being studied in the phase III setting as a maintenance strategy following front-line chemotherapy. 63 Although the long-term administration of chemo therapy in this setting is impractical because of mounting toxicity, the use of agents targeting biological processes raise the question of administration duration. Theoretically, the high percentage of recurrence, coupled with the cytostatic potential of these newer biologically targeted agents, suggests that prolonged administration could be advantageous. However, cost, toxicity, and potential adverse effects on tumour biology are relevant remaining questions, which rival those of overall survival. 64 There is no specific hallmark of recurrent disease; many patients will report symptoms rivalling those at initial presentation, while others will acknowledge new symptoms such as lymphoedema, shortness of breath, bloating or pain. 64 Some patients are diagnosed with measurable recurrent disease solely on the basis of imaging or physical exam, while others might only be identified by serially rising biomarkers (such as CA-125 or HE4 levels) in the absence of imageable disease. These patients with biological or 'chemical' recurrence frequently have small-volume disease on surgical investigation; however, the value of treatment in the absence of symptoms has been strongly challenged. 65 A recent phase III study examined the role and impact of serial CA-125 surveillance. 66 In this study, 1,442 women in complete clinical remission following front-line therapy underwent CA-125 evaluation every 3 months. Both patients and investigators were blinded to the results. Women who remained asympto matic, but whose CA-125 levels exceeded twice the upper limit of normal (n = 527) were randomly assigned to immediate unblinding and subsequent chemotherapy or to continued blinding with intervention delayed until the time of a clinical or symptomatic recurrence. As anticipated, second-line treatment was started a median of 5 months earlier in the immediate unblinding arm. However, at a median follow-up of 57 months from random ization, this early treatment did not contribute to improved survival (hazard ratio [HR] = 0.98; 95% CI 0.80-1.20) or a longer remission duration. Furthermore, immediate treatment had an adverse impact on quality of life. 66 Critics have argued that following patients l ongitudinally with biomarkers might help identify patients for surgical treatment at recurrence. 67 This potential for early identification was highlighted in a small study (n = 74) of women with recurrent ovarian cancer who underwent secondary cytoreduction. 67 An evaluation of factors associated with an optimal outcome (<1 cm tumour residuum) identified that an early rise in CA-125 hastened surgical intervention by a median time of over 11 weeks. Despite this finding, it is still unclear whether earlier surgical intervention based on a rising biomarker translates into improved overall survival. Nonetheless, many patients are still surveyed with serial biomarkers along with physical examination in the hope that treatment at recurrence with newer active chemotherapeutic agents will improve survival. Further data, however, are needed to confirm this hopeful hypothesis.
Once recurrent disease is suspected or documented, the choice of treatment traditionally has been determined by consideration of the interval from prior therapy and specifically the time from last prior platinum-based chemo therapy. These general definitions, and the approach to treatment for patients within these categories, are used frequently in clinical practice. In actuality, the treatment-free interval irrespective of previ ous exposure to platinum-based therapy can be considered as well. The hope moving forward is that these crude categories that determine treatment are replaced by more-predictive, gene-expression and pathway-based assessments that facilitate individualized therapies.
Categories of recurrence
Platinum-refractory disease Patients who have platinum-refractory disease have tumours that essentially fail to respond to front-line therapy as exhibited by ongoing growth during initial platinum-based therapy. Prognosis for these patients is very poor, characterized by low response rates (<10%) and overall survival (<12 months); 68 however, alternative platinum-based doublets and some singleagent regimens have demonstrated activity in this patient population.
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Platinum-resistant disease Platinum-resistant disease is defined as patients whose recurrence is documented within 6 months of platinum-based therapy; these patients usually receive a non-platinum single-agent regimen as second-line treatment. Most-common chemotherapeutic choices include docetaxel, 70 pegylated liposomal doxorubicin (PLD), 71, 72 topotecan, 71, 73 and weekly paclitaxel (Table 3) . [74] [75] [76] As one can appreciate, the outcome data are not impressive and novel compounds and approaches are necessary as chemo therapeutics alone have not been highly successful in this cohort. One such novel approach has been the addition of bevacizumab to standard single-agent chemotherapy that has demonstrated improved responses and PFS. 77 In this recently reported study, 361 women with recurrent, platinum-resistant (stratified for treatmentfree interval less than 3 months, and 3-6 months and prior antiangiogenesis therapy) ovarian cancer and two or fewer prior therapies were randomly assigned to one of three chemotherapy options versus these same options plus bevacizumab. The chemotherapy cohorts (all limited to approximately 120 patients) were weekly paclitaxel (80 mg/m 2 , days 1-5 of a 21-day cycle). The experimental group included patients with the same chemotherapy plus bevacizumab (10 mg/kg every 14 days or 15 mg/kg every 21 days, as appropriate for the chemotherapy schedule) and both cohorts were treated until disease progression. Prior antiangiogenesis therapy use was infrequent (approximately 7-8%). Overall, the experimental arm outperformed the control arm for PFS (median: 6.7 months versus 3.4 months; HR = 0.48; 95% CI 0.38-0.60) and response (31% versus 13%, RECIST and/or GCIG CA-125 criteri a, P <0.001). Subgroup evaluation identified a robust effect across all strata. Myelosuppression was the most common grade 3 or 4 event (16-17% both cohorts) with peripheral neuropathy (5%) and hand-foot syndrome (4.5%) being more common in the experimental cohort compared to the control. Overall survival has not been reported, but publication is anticipated.
Platinum-sensitive disease
Platinum-sensitive disease is defined as patients whose recurrence is documented greater than 6 months after platinum-based therapy. 64, 68 These patients have a much better prognosis than the categories above in terms of longevity, as many will respond to multiple regimens. Generally these patients are treated with a platinumbased combination. Platinum-sensitive disease is a broad category that can be rather heterogeneous, because those who recur just over 6 months after receiving platinumbased therapy can behave more like platinum-resistant patients than those who recur later; response rates and time-to-event data improve incrementally as the time interval from prior chemotherapy until recurrence increases. Thus, some authors have advocated that those who recur earlier, specifically between 6-12 months, be labelled as partially or intermediately sensitive. 78 These patients can be treated in a similar way to platinumsensitive patients who recur after 12 months; however, some have advocated for the consideration of singleagent therapies used in platinum-resistant disease or non-platinum-based combinations. 78 A number of platinum-based combinations can be used in patients with platinum-sensitive disease (Table 4) . Often, patients are treated with platinumbased and taxane-based chemotherapy again; however, concern for cumulative neuropathy can limit this choice.
Furthermore, if the time from previous platinum and taxane treatment has been short, then often a regimen is selected that incorporates an alternative to taxane, such as gemcitabine or PLD. Besides altering the toxicity profile, a different mechanism of action is invoked by changing the second agent paired with platinum. More recently, with the discovery of other active cytotoxic agents, non-platinum combinations are becoming more common. 79 Contemporary trials in platinum-sensitive disease have incorporated targeted biological agents, as outlined below in the novel agent focus section.
Recurrent disease therapy
Most patients diagnosed with recurrent disease will have a multifocal distribution of implants that mimic their presentation at initial diagnosis. In this respect, it is not difficult to understand clinicians' and patients' interest in 'secondary' surgical cytoreduction. Unfortunately, despite the significant attention this topic has received from clinical investigation, guidance as to its role in the setting of recurrent disease is not clear. 18 In addition, interpretation of the available data is difficult at the minimum, and hazard ous at the extreme, because of the inherent selection bias that exists in reviews of clinical experience at one or more institutions. Even reports that are based on observations of prospectively collected patients cannot be reliably compared to historical observations owing to inability to control for variations in practice patterns, patient selection and assessment models. This situation has placed a premium on phase III investigation, which fortunately is underway.
Despite the uncertainty, most practitioners strongly advocate that secondary cytoreduction has a place among carefully selected patients. 80 One clear factor in the consideration for surgical intervention in medically fit patients is their underlying potential to respond to adjuvant therapy. Although this is an imperfect science, the probability of responding to secondary chemotherapy seems to be a positively sloped linear relationship with treatment and platinum-free interval. 77 In this regard, patients with long treatment or platinum-free intervals (>24 months from first-line treatment completion) have anticipated outcomes, such as response rate, PFS and overall survival similar to those with treatmentnaive disease. 81 The impact of even a subtotal resection may have merit in this situation. 82, 83 However, given that the median PFS from most phase III front-line trials ranges between 10 and 24 months, the majority of candidates with recurrent disease will fall into a category of intermediate and largely unknown potential chemosensitivity. In a multivariate analysis of overall survival of 46 women undergoing secondary cytoreduction for recurrent disease, 84 time to recurrence of 24 months or longer, and resection to no visible residual disease were the only independent predictors of survival. The optimal resection rate (complete resection to no visible disease) in this study was 41%. In a prospective study of 106 patients with recurrence 6 months or longer after primary treatment, 85 82% of the patients were rendered free of visible tumour. In the multivariate analysis, 84 four variables were independent predictors of survival: disease-free interval, residual disease after secondary surgery, administration of chemotherapy before secondary surgery, and size of recurrent tumour. The authors concluded that complete resection can be obtained in most selected patients and the procedure should be considered before the administration of second-line chemotherapy. The vast majority of published series on the topic have reiterated the importance of treatment or platinum-free interval and post-operative disease residuum on treatment 'success'; 1 suggesting that patient and perioperative co-factors can be identified within individual series. Nevertheless, patient selection tools with sufficient external validity are problematic and limited.
Different strategies have been assessed in an effort to address this deficiency. Radiological evaluation has been frequently cited by investigators, but predictive criteria identifying optimal candidates are poorly reproducible between institutions. 82 Endoscopic evaluation, similar to that used by clinicians to identify appropri ate candidates for primary cytoreduction, has also been used. Benedetti-Panici and colleagues reported that no visible residual disease was achieved in 79% of patients prescreened by imaging and exam who subsequently underwent pre resection endoscopy. 86 As in other trials, patient selection was tightly controlled with 60% of the operative sample presenting with solitary recurrence masses. The AGO identified a panel of features in their initial retrospective study on the topic (DESKTOP I trial), 87 and validated their predictive model in a subsequent study. 88 They found that patients who had a performance status of 0 or 1, with early stage disease, or had no visible tumour residuum following initial surgical cyto reduction and no ascites were likely (>67%) to have a complete surgical cytoreduction. Currently, the criteria are being used to determine eligibility for a phase III trial (DESKTOP III 89 ) currently underway. Another phase III study ) is being conducted to evaluate not only surgical cytoreduction, but also adjuvant chemotherapy in platinum-sensitive patients. In this trial, eligi bility for secondary surgery is limited to measurable disease, treatment-free interval of greater than 6 months and investigator opinion of complete cytoreduction. A third randomized phase III trial is also recently underway using the iMODEL scoring system for eligibility. 81, 91 This trial will randomize eligible patients (score of ≤4.7) to secondary cytoreduction followed by chemotherapy versus chemotherapy alone. Each of these phase III studies are targeting overall survival as their primary end point.
A large, multicentre-collected data set of in divi dual patients undergoing secondary cytoreduction was interro gated for prognostic and selection criteria character istics. 83, 92 In the first report, platinum-free interval, ascites, recurrent disease distribution, and postoperative primary residual disease were independently predictive of overall survival. From weighted scoring in a nomogram, low-risk and high-risk cohorts could be discriminated (low-risk = score 0-2 versus highrisk = score 3-8, HR = 3.65, 95% CI 3.05-4.4). 83 In the second report aimed at candidate selection (removing secondary cytoreduction outcome) the risk model added FIGO stage, performance status, and CA-125 level. 92 The REVIEWS nomogram dropped disease localization and primary cytoreduction outcome, and lowered the discriminant on platinum-free interval from 23.1 months to 16 months. The nomogram identified high-risk (score >4.8) surgical cohorts (external validity for complete resection AUC = 0.68), which was also prognostic for overall survival. When secondary cytoreduction outcome was added, the model further demonstrated prognostic value, with differential benefits seen among different risk cohorts with the same post operative outcome (optimal versus suboptimal). Collectively, the data support interventional effects but, as mentioned, lack selection and treatment-effect bias.
Novel agent focus
Planned clinical development Based on the initial encouraging activity of bevacizumab in newly diagnosed as well as recurrent ovarian cancer, many late-stage clinical trials have focused on other agents targeting the tumour vasculature. Inhibiting VEGF has been effective in shrinking tumours as well as prolonging PFS. This class of agents even has activity when used as single agents. 93 Other angiogenesis pathways involved in ovarian cancer pathogenesis include PDGF and FGF. 10 Two studies have completed enrolment and the results are expected soon. The first assessed nintedanib, an oral agent that targets VEGFR-1, VEGFR-2, and VEGFR-3, PDGFR-α/β, FGFR-1, FGFR-2, and FGFR-3, members of the v-src sarcoma viral oncogene homolog (Src) family, and Flt-3. AGO-OVAR12/LUME-Ovar1 is a placebo-controlled phase III trial that is investigating the combination of nintedanib with carboplatinpaclitaxel in the first-line setting followed by nintedanib maintenance therapy until disease progression or for a maximum of 120 weeks after randomization in patients with epi thelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. 61 The second trial (AGO-OVAR 16) is assessing pazopanib, another oral agent that targets VEGFR-1, VEGFR-2, and VEGFR-3, PDGFR-α/β, FGFR-1 and FGFR-3, and c-kit. In light of its antitumour activity and acceptable tolerability, this compound is being evaluated in a phase III trial investigating pazopanib versus placebo for 24 months as maintenance therapy in patients with non-bulky stage II-IV epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer with a complete response, partial response, or stable disease after surgical debulking and at least five cycles of first-line platinum-taxane chemotherapy.
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More recently, angiopoietin 1 and 2 have been identi fie d as important drivers of angiogenesis in ovarian cancer via their binding to the Tie2 receptor. [94] [95] [96] Both angiopoietin 1 and 2 can be inactivated by trebananib, an intravenous peptide-Fc fusion protein (or peptibody). This agent differs from VEGF inhibiting agents as it has not been shown to be associated with hypertension or bowel perforations, although oedema has been noted as an attributable toxicity. Several phase III clinical trials (TRINOVA-1,  97 TRINOVA-2,  98 and  TRINOVA-3 62 ) are evaluating trebananib in epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. TRINOVA-1 is evaluating paclitaxel in combi nation with either trebananib or placebo in previously treated patients. The initiation date was October 2010 and the estimated primary completion date is July 2013. TRINOVA-2 is evaluating PLD in combination with either placebo or trebananib in a similar setting. To be eligible for both the TRINOVA-1 and TRINOVA-2 trials, patients must also have ECOG performance status of 0 or 1 and have received ≤three prior platinum-based chemo therapy regimen(s) or had a platinum-free interval of <12 months from the first platinum-based therapy. In TRINOVA-3, trebananib is being combined with first-line carboplatin-paclitaxel. The study was initiated in December 2011, with final data collection for the primary end point of PFS expected in 2016.
The folate (vitamin B9) receptor is overexpressed on the surface of almost all epithelial ovarian cancers making it an excellent 'tumour-associated antigen' . 69 Two strategies have been used to preferentially target carcinomas overexpressing the folate receptor. First, farletuzumab is a humanized monocolonal antibody to folate receptor alpha and is being evaluated in a phase III placebo controlled trial with second-line carboplatin-paclitaxel in patients with platinum-sensitive relapsed ovarian cancer. 97 Second, folate can be linked to traditional cytotoxics. Vintafolide is an intravenous conjugate consisting of folate linked to a potent vinca alkaloid chemo therapy agent, desacetylvinblastine mono hydrazide (DAVLBH). It is currently being evaluated in a phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial 100 ) and uses an investigational companion diagnostic agent, etarfolatide (EC20).
Finally, cytotoxins alone continue to have a major role in treating ovarian cancer and will continue to be studied in clinical trials. Trabectedin is a novel marine anti neoplastic alkaloid with a unique mechanism of action originally isolated from the Caribbean sea squirt, Ecteinascidia turbinate. Trabectedin binds covalently to the minor groove of DNA, bending DNA towards the major groove, and disrupts transcription leading to G 2 -M cell-cycle arrest and ultimately apoptosis. 101 It is being studied in a randomized phase III trial in combi nation with PLD compared to carboplatin-PLD in patients with partially-platinum-sensitive recurrent ovarian cancer (progression-free interval 6-12 months). This study will assess if prolonging the platinum-free interval can improve survival and is known as the INternational OVArian cancer patients Trial with YONdelis.
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Biology and new directions in drug development New discovery knowledge and technological advances are creating unprecedented opportunities for accelerating identification of new targets and compounds capable of engaging the biological drivers of epithelial ovarian cancer. Paramount to the translation of this know ledge is the realization of the fact that ovarian cancer is actually many diseases rather than a single entity. The diverse histological subtypes (that is, serous, mucinous, clear cell, and endometrioid) are highly distinct diseaseunique molecular features (Figure 2) . [103] [104] [105] Even within the same histological subtype (for example, serous cancers), lowgrade and high-grade differentiation is related to very distinct molecular features and clinical behaviour. 103 In recognition of these findings, a Rare Tumor Committee has been formed at the NRG (formerly, GOG) to develop histology-specific trials. One completed trial in patients with low-grade serous ovarian cancer evaluated the MEK inhibitor, AZD6244, in a single-arm, two-stage design. 106 An objective response rate was observed in 16% of patients, with a median PFS of 11 months. This response compares favourably with the experience with chemotherapy where response rates to chemotherapy have been less than 5%. 107 Other trials in mucinous (Src, HER2, and MEK inhibitors), clear cell (PI3K pathway, HIF-1α, and MET inhibitors) and endometrioid (PI3K pathway inhibitors, and aromatase inhibitors) ovarian cancer are being designed to exploit pathway aberrations that have been identified.
Remarkably, some ovarian and breast cancers have more in common with each other than with other cancers from those organs. For example, high-grade serous ovarian cancer and basal breast cancer have more molecu lar similarities with each other than basal breast cancers do with luminal breast cancer. 108 The term ovarian cancer might in itself require re-thinking. Although it has been used as a broad term to capture many of the malignancies noted above, it has become clear that a considerable proportion of tumours do not actually arise from the ovarian tissues (for example, distal fallopian tube as a source for many high-grade serous cancers; endo metriosis as a source for endometrioid and clear-cell cancers). 103 However, given the current use of this term in the commu nity, additional scientific debate will be required prior to making any changes in the terminology.
Given the high prevalence and mortality associated with high-grade serous ovarian cancer, much of the large-scale discovery work has focused on this disease. Although there were few surprises from The Cancer Genome Atlas (TCGA) work, it functioned to confirm many points including: TP53 mutations are present in almost all tumours (96%); there is a high prevalence of somatic mutations, but there is a low prevalence of recurrent mutations (some genes with recurrent mutations include NF1, BRCA1, BRCA2, RB1, and CDK12); and there are large-scale copy number aberrations. 5 Initial analyses also suggest that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in ovarian cancer pathogenesis. 5 Expanded and integrated analyses of the TCGA data have revealed that among women with high-grade serous ovarian cancer, BRCA2 mutation is associated with significantly better survival, improved chemotherapy response, and genome instability compared to those with BRCA1 mutation or BRCA1/2 wild type. 109 Such molecular knowledge has already had an impact on developing personalized therapies. For example, poly (ADP)ribose polymerase (PARP) inhibitors have been developed to leverage BRCA (and other homologous recombination genes) dysfunction by promoting mitotic catastrophe in targeting the compensatory DNA-repair mechanism. 110 Several clinical trials have documented proof of the mechanism, including a large phase I study of the PARP inhibitor olaparib in women with BRCA1 or BRCA2 germline mutations. 111 In the expansion cohort of patients with ovarian cancer, objective responses were noted prompting phase II studies. In one randomized, three-arm phase II trial, two doses of olaparib (200 mg twice daily and 400 mg twice daily) were compared to PLD (50 mg/m 2 ) in women carrying a germline BRCA1 or BRCA2 mutation, with a platinum-free interval of 12 months or less. 112 The median PFS was similar between the three arms (6.5 months in the 200-mg olaparib group, 8.8 months in the 400-mg group, and 7.1 months in the PLD arm), as was response. The impressive performance of the PLD arm highlights the impact DNA-damaging agents have in this cohort of women. A second provocative randomized phase II trial addressed the impact of maintenance olaparib in women with platinum-sensitive recurrent ovarian cancer who achieved a response to platinum-based chemotherapy. 113 In this trial, 265 women with known BRCA mutation status (positive: 22%, wildtype: 15%) and unknown status were treated with olaparib (400 mg twice daily) or placebo until disease progression. Median PFS was significantly longer in the olaparib arm (median: 8.4 months versus 4.8 months; HR = 0.35, 95% CI 0.25-0.49). Similarly, a randomized phase II trial of paclitaxel-carboplatin with or without olaparib followed by olaparib or placebo maintenance has been reported. 114 In this trial, 162 women with high-grade serous ovarian cancer were treated with combination therapy for up to six cycles and then proceeded to maintenance therapy in the absence of disease progression. To accommodate the combination with chemotherapy, olaparib was administered at 200 mg twice daily during chemotherapy and at 400 mg twice daily during maintenance; carboplatin was given at AUC 4 in this arm as well. Overall, the median PFS was extended significantly in the experimental arm (median: 12.2 months versus 9.6 months; HR = 0.51, 95% CI 0.34-0.77). Of interest, it seemed that separation of the curves only occurred after the completion of chemo therapy. Extensive investigation with other PARP inhibitors is underway. [115] [116] [117] [118] Targeting tumours with homologous recombination defects using additional drugs that are complementary to PARP inhibitors, such as PI3K/Akt/mTOR and antiangiogenesis inhibitors, offers near-term opportunities. Moreover, emerging technologies, such as the use of biocompatible nanoparticles for systemic therapeutic gene silencing using RNA interference, offer opportunities for rapidly functionalizing the genome and targeting even the 'undruggable' . 119 Given the high rate of genomic instability in highgrade serous ovarian cancer, targeting the stroma has been considered an attractive option. As discussed previously, arguably the most clinically mature is the platform for targeting the VEGF-VEGFR axis. Drugs targeting this pathway, such as bevacizumab, have demonstrated clinical activity, although only to a modest extent in the upfront adjuvant setting in combination with chemotherapy. 51 Understanding the primary resistance and adaptive responses to anti-VEGF therapy constitutes an important area of current research. The mechanisms for such evasive responses include hypoxia, adaptation of tumour endothelial cells, leveraged alternative growth factors (FGFR and so on) and alternative signalling (Dll4-Notch), and roles of other cell types in the tumour microenvironment including pericytes, fibroblasts, leukocytes, and platelets. 10 Many of these targeted approaches will likely offer therapeutic opportunities in combination with anti-VEGF drugs and other vascular effecting agents.
The mechanisms of cytotoxic drug resistance in e pi thelial ovarian cancer remain elusive and indeed are probably very pleiotropic. In other words, the mechanisms of resistance to platinum drugs and taxanes probably translate to cross-resistance to other cytotoxic agents. This is both a biological as well as a clinical phenomenon and has led clinicians to use the term 'chemotherapyresistant' recurrent ovarian cancer rather than the more restrictive term 'platinum-resistant' disease. Accordingly, no studies have shown any improvement in survival when treating this subset of patients. In order to circumvent resistance to traditional approved agents in ovarian cancer, clinical trials are ongoing that investigate a host of targeted agents including mitotic checkpoint inhibitors, PI3K/AKT inhibitors and agents engaging HER3. 120, 121 In this context, collecting tumour tissue at relapse for genomic analysis and comparison with pre-treatment tumour data, is of critical importance.
To accelerate clinical drug development and to address practically the massive number of new biologically targeted drugs, improvements in clinical trial design are needed. It is simply impractical to carry out the number of phase III trials needed to study the new agents and a greater emphasis should be placed on earlier phase trial designs that incorporate molecular studies. Phase 0 trials looking at target engagement and mechanisms of action may offer earlier and faster opportunities for readouts on pathway inhibition. 122, 123 Moreover, contemporary clinical trials should avoid aggregating the various ovarian cancer histological subtypes unless there is compelling scientific reason to do so. The molecular correlates or biomarkers could be considered in three broad contexts: resistance (which drugs are likely not to work); response (which drugs are likely to work in a given patient); and risk (which drugs pose a high risk of adverse events for a given patient). 124 Although this strategy further divides the therapeutic population, it provides the setting and context to demonstrate the impact of targeted, actionable aberrations and associated treatments that may best translate into significant response metrics.
Conclusions
Ovarian cancer remains a formidable management challenge as most patients present with disease burdens that are difficult to completely eradicate, despite excellent response to state-of-the-art therapies and treatment approaches. It is clear from existing survival data that early detection and prevention have the greatest potential to permanently and substantially effect long-term outcomes. Current investigation of 'targeted' therapeutics is identifying individuals with disease characteristics that are uniquely vulnerable to certain agents. However, in the absence of early detection, these are likely to have limited impact on overall survival. General population screening, such as that being conducted in the UK (UKCTOC Study) seems to be more promising to achieve the kind of stage migration that could impact overall survival. 125 However, low prevalence of disease and imperfect s creening a lgorithms are placing high bars on reaching this goal.
Measurable impact on this disease's clinical course requires careful consideration of all aspects of care including how it is delivered and how much it costs. Clinical drug development is grossly outpacing clinical investigation, and untethered oversight is bringing multitudes of agents to patients with limited promise of effecting measureable alterations in the natural history. Careful use of patient resources combined with robust translational science is necessary to maximize the risk:benefit considerations as we interrogate new mechanisms of action and propose the next generation of iterative c linical investigation.
Review criteria
We reviewed clinical data from online databases such as MEDLINE, PubMed, and Google Scholar, as well as abstracts from International Oncology meetings regarding topics of ovarian cancer from 1950 to 2012. Search terms used were "ovarian cancer", "primary peritoneal cancer", "fallopian tube cancer", "epithelial cancer", "surgical debulking", "secondary cytoreduction", "chemotherapy", "targeted therapeutics", "maintenance therapy", and "clinical trials" to identify publications and abstracts underlying treatment standards and emerging technologies for management of this disease. Clinical trials were identified by their ClinicalTrials.gov identifier.
